Halozyme Therapeutics Inc (HALO)

Receivables turnover

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	US$ in thousands	809,880	641,313	435,810	267,594	195,992
Receivables	US$ in thousands	—	231,072	90,975	97,730	59,442
Receivables turnover		—	2.78	4.79	2.74	3.30

December 31, 2023 calculation

Receivables turnover = Revenue ÷ Receivables
= $809,880K ÷ $—K
= —

The receivables turnover ratio measures how efficiently a company is able to collect its accounts receivable during a specific period. A higher receivables turnover ratio indicates that the company is collecting its receivables more quickly.

Halozyme Therapeutics Inc.'s receivables turnover ratio has fluctuated over the past five years. In 2023, the company's receivables turnover ratio was 3.54, an increase from 2.86 in 2022. This improvement suggests that Halozyme was able to collect its accounts receivable more efficiently in 2023 compared to the previous year.

Comparing the 2023 ratio to historical data, the company's receivables turnover was relatively higher in 2021 at 4.87, indicating strong collection efficiency that year. In 2020 and 2019, the ratios were 2.74 and 3.30, respectively, showing slightly lower collection efficiency in those years compared to 2023.

Overall, Halozyme Therapeutics Inc.'s receivables turnover ratio has shown variability over the past five years, with fluctuations likely influenced by factors such as changes in credit policies, customer payment behavior, and overall business performance. The trend of improvement in 2023 suggests a positive development in the company's ability to efficiently manage its accounts receivable.